Form Approved
OMB NO: 0920-0740
EXPIRATION DATE: 05/31/2012
Medical Monitoring Project (MMP)
Medical Record Abstraction Form
2012 Surveillance Period Inpatient Form (SPIF)
VERSION 7.1.0
O
PTIONAL-
FOR LOCAL USE ONLY
MMP SPIF v7.1.0
MMP Participant ID:
Date
of Admission:
A Facility ID:
(ID of facility where abstraction is being conducted)
Inpatient medical record number:
Patient name:
Patient residence:
Street:
City/County: State:
ZIP code:
Physician name:
|
DEPARTMENT OF HEALTH AND
HUMAN SERVICES Centers
for Disease Control & Prevention
M
edical
Monitoring Project (MMP)
Medical Record Abstraction Form
2012 Surveillance Period Inpatient Form (SPIF)
V7.1.0
I. ABSTRACTION AND IDENTIFICATION |
||||
MMP Participant ID: |
||||
Surveillance Period (SP)
SP start date:
(12 months prior to date of interview OR 1st contact attempt if no interview obtained) |
SP end date:
(date of interview OR 1st contact attempt if no interview obtained)
|
|||
Date of abstraction: |
Abstractor ID: |
|||
Date of admission:
|
Date of discharge:
|
|||
Abstraction Facility ID:
(ID of facility where abstraction is being conducted)
|
|
|||
Was the documented care abstracted with this form given at another facility (i.e., outside the Abstraction Facility)?
|
||||
|
|
Yes Complete
information about the “Care” Facility
|
Enter Care Facility ID or indicate that Care Facility was not documented or was outside jurisdiction
Facility ID
(ID of the facility where the documented care was provided) |
|
|
|
|
||
|
|
No Continue to Section II below |
|
|
II. SURVEILLANCE PERIOD INPATIENT FORM SECTIONS – OPTIONAL |
||||
Is there documentation of any of the following during this inpatient stay?
|
||||
(AIDS OI)
|
|
|||
|
|
|||
to admission
|
|
|||
to discharge
|
|
III. AIDS DEFINING OPPORTUNISTIC ILLNESSES (AIDS OI) |
||||
Is there documentation any new or existing diagnoses of AIDS defining opportunistic illnesses (AIDS OI) during this inpatient stay?
|
||||
1 |
14 |
|||
2 |
15 |
|||
3 |
16 |
|||
4 |
17 extrapulmonary |
|||
5 |
18 |
|||
6 |
19 |
|||
7 |
20 disseminated or extrapulmonary |
|||
8 |
21 |
|||
9 bronchitis, pneumonitis, or esophagitis |
22 |
|||
10 |
23 |
|||
11 |
24 |
|||
12 |
25 |
|||
13 |
26 |
|||
IV. CONDITIONS OTHER THAN AIDS OI |
||||
Is there documentation of any new or existing diagnoses of conditions other than AIDS OI during this inpatient stay?
|
||||
1 |
19 |
37 deficiency) |
55 |
|
2 |
20 |
38 |
56 |
|
3 |
21 |
39 |
57 schizophrenia |
|
4 |
22 >100F for 2+ weeks* |
40 |
58 |
|
5 |
23 disease (GERD) |
41 |
59 |
|
6 |
24 |
42 |
60 |
|
7 |
25 |
43 |
61 |
|
8 |
26 |
44 |
62 |
|
9 HIV or unknown cause |
27 |
45 disease/disorder) |
63 |
|
10 bacterial) |
28 |
46 weakness or changes) |
64 Syndrome |
|
11 physician |
29 drug-induced |
47 stone) |
65 hemorrhagic |
|
12 type 1 |
30 |
48 damage) |
66 |
|
13 type 2 |
31 (Hodgkin’s disease) |
49 |
67 idiopathic (ITP) |
|
14
|
32 (HPV) infection |
50 |
68 severe; blindness |
|
15 |
33 |
51 |
69 |
|
16 |
34 |
52 |
70 genital |
|
17 |
35 pressure) |
53 osteoporosis |
*in absence of a known cause |
|
18 |
36 |
54 |
|
IV. CONDITIONS OTHER THAN AIDS OI cont’d |
|||||
71
|
|||||
72
|
|||||
73
|
|||||
74 |
|||||
75
|
|||||
76 |
|||||
77 |
|||||
V. ANTIRETROVIRAL THERAPY (ART) |
|||||
Is there documentation of prescription of antiretroviral therapy (ART) during this inpatient stay?
|
|||||
Prescription or continuation closest to: |
|
||||
Admission |
Discharge |
Name |
Abbreviation |
Also Known As |
Group |
1 |
1 |
Abacavir |
ABC |
Ziagen |
NRTI |
2 |
2 |
Amprenavir |
APV |
Agenerase |
PI |
3 |
3 |
Atazanavir |
ATV |
Reyataz |
PI |
4 |
4 |
Atripla |
EFV/FTC/TDF |
|
Multi-class |
5 |
5 |
Combivir |
AZT/3TC |
|
CNRTI |
6 |
6 |
Darunavir |
DRV, TMC 114 |
Prezista |
PI |
7 |
7 |
Delavirdine |
DLV |
Rescriptor |
NNRTI |
8 |
8 |
Didanosine |
Ddl |
Videx |
NRTI |
9 |
9 |
Efavirenz |
EFV |
Sustiva |
NNRTI |
10 |
10 |
Emtricitabine |
FTC |
Emtriva |
NRTI |
11 |
11 |
Enfuvirtide |
ENF, T-20 |
Fuzeon |
FI |
12 |
12 |
Epzicom |
ABC/3TC |
|
CNRTI |
13 |
13 |
Etravirine (formerly TMC125) |
ETR |
Intelence |
NNRTI |
14 |
14 |
Fosamprenavir |
FPV |
Lexiva |
PI |
15 |
15 |
Indinavir |
IDV |
Crixivan |
PI |
16 |
16 |
Lamivudine |
3TC |
Epivir |
NRTI |
17 |
17 |
Lopinavir/Ritonavir |
LPV/RTV |
Kaletra, Meltrex |
CNRTI |
18 |
18 |
Maraviroc |
MRC |
Selzentry |
Entry inhibitor |
19 |
19 |
Nelfinavir |
NFV |
Viracept |
PI |
20 |
20 |
Nevirapine |
NVP |
Viramune |
NNRTI |
21 |
21 |
Raltegravir (formerly MK-0518) |
RAL |
Isentress |
Integrase inhibitor |
22 |
22 |
Ritonavir |
RTV |
Norvir |
PI |
23 |
23 |
Saquinavir |
SQV-HGC |
Invirase, Fortovase |
PI |
24 |
24 |
Stavudine |
d4T |
Zerit |
NRTI |
25 |
25 |
Tenofovir |
TDF |
Viread |
NRTI |
26 |
26 |
Tipranavir |
TPV |
Aptivus |
PI |
27 |
27 |
Trizivir |
ABC/3TC/AZT |
|
CNRTI |
28 |
28 |
Truvada |
FTC/TDF |
|
CNRTI |
V. ANTIRETROVIRAL THERAPY (ART) cont’d |
||||||||
Prescription or continuation closest to: |
|
|||||||
Admission |
Discharge |
Name |
Abbreviation |
Also Known As |
Group |
|||
29 |
29 |
Zalcitabine |
ddC |
Hivid |
NRTI |
|||
30 |
30 |
Zidovudine |
AZT |
Retrovir |
NRTI |
|||
31 |
31 |
Other, Specify: |
||||||
32 |
32 |
Other, Specify: |
||||||
33 |
33 |
Other, Specify: |
||||||
VI. OTHER MEDICATIONS |
||||||||
Is there documentation of prescription or continuation of medications other than ART during this inpatient stay?
|
||||||||
1 |
acarbose |
35 |
dapsone (DDS) |
|||||
2 |
acetominophen/hydrocodone |
36 |
darifenacin |
|||||
3 |
acetominophen/oxycodone |
37 |
dexamethasone |
|||||
4 |
acyclovir |
38 |
diphenhydramine |
|||||
5 |
adefovir |
39 |
doxorubicin |
|||||
6 |
albuterol |
40 |
doxorubicin lipsomal |
|||||
7 |
albuterol/ipratropium |
41 |
doxycycline |
|||||
8 |
aldesleukin |
42 |
dronabinol |
|||||
9 |
alprazolam |
43 |
enalapril |
|||||
10 |
amikacin |
44 |
enalapril/hydrochlorothiazide (HCTZ) |
|||||
11 |
amitriptyline |
45 |
entecavir |
|||||
12 |
amitriptyline/chlordiazepoxide |
46 |
epoetin alfa (EPO) |
|||||
13 |
amoxicillin |
47 |
escitalopram |
|||||
14 |
amoxicillin/clavulanate |
48 |
esomeprazole |
|||||
15 |
aspirin (ASA) |
49 |
ethambutol |
|||||
16 |
atenolol |
50 |
ethionamide |
|||||
17 |
atorvastatin |
51 |
famotidine |
|||||
18 |
azithromycin |
52 |
fexofenadine |
|||||
19 |
baclofen |
53 |
filgrastim |
|||||
20 |
bupropion |
54 |
folinic acid |
|||||
21 |
buspirone |
55 |
fluconazole |
|||||
22 |
butalbital/aspirin |
56 |
fludrocortisone |
|||||
23 |
butalbital/aspirin/caffeine (BAC) |
57 |
fluoxetine |
|||||
24 |
calcitrol |
58 |
fluphenazine |
|||||
25 |
capreomycin |
59 |
fluticasone |
|||||
26 |
cetirizine |
60 |
fluticasone/salmeterol |
|||||
27 |
chlorpropamide |
61 |
fluvastatin |
|||||
28 |
cimetidine |
62 |
foscarnet |
|||||
29 |
ciprofloxacin |
63 |
gabapentin |
|||||
30 |
citalopram |
64 |
gatifloxacin |
|||||
31 |
clonazepam |
65 |
gemfibrozil |
|||||
32 |
cromolyn |
66 |
hydrochlorothiazide (HCTZ) |
|||||
33 |
cycloserine |
67 |
hydrochlorothiazide (HCTZ)/methyldopa |
|||||
34 |
cyclosporine |
68 |
hydrochlorothiazide (HCTZ)/metoprolol |
VI. OTHER MEDICATIONS cont’d |
|||
69 |
hydrochlorothiazide (HCTZ)/triamterene |
108 |
penicillin |
70 |
imiquimod |
109 |
phenytoin |
71 |
insulin (inhaled or injectable) |
110 |
pioglitazone |
72 |
interferon alphacon-1 |
111 |
podofilox topical |
73 |
interferon alfa 2a |
112 |
podophyllin topical |
74 |
interferon alfa 2b |
113 |
pravastatin |
75 |
iodoquinol |
114 |
prednisone |
76 |
isoniazid (INH) |
115 |
propranolol |
77 |
isoniazid (INH)/pyrazinamide (PZA)/rifampin |
116 |
propranolol/hydrochlorothiazide (HCTZ) |
78 |
isoniazid (INH)/rifampin |
117 |
pyrazinamide (PZA) |
79 |
kanamycin |
118 |
ranitidine |
80 |
lansoprazole |
119 |
ribavirin |
81 |
lansoprazole/amoxicillin/clarithromycin |
120 |
rifabutin |
82 |
levofloxacin |
121 |
rifampin |
83 |
levothyroxine |
122 |
rifapentine |
84 |
lisinopril |
123 |
rosiglitazone |
85 |
lithium |
124 |
rosiglitazone/glemepiride |
86 |
loxapine |
125 |
rosuvastatin |
87 |
megestrol |
126 |
sertraline |
88 |
metformin |
127 |
sildenafil |
89 |
methadone |
128 |
somatropin |
90 |
metoclopramide |
129 |
streptomycin |
91 |
metoprolol |
130 |
tadalafil |
92 |
mirtazapine |
131 |
tamsulosin |
93 |
moxifloxacin |
132 |
telbivudine |
94 |
nalbuphine |
133 |
testosterone |
95 |
niacin |
134 |
tinidazole |
96 |
nifedipine |
135 |
trazadone |
97 |
nizatidine |
136 |
triamcinolone nasal |
98 |
octreotide |
137 |
trichloracetic acid (TCA) topical |
99 |
olanzapine |
138 |
trimethoprim/sulfamethoxazole (TMP/SMZ) |
100 |
omeprazole |
139 |
valacyclovir |
101 |
oxycodone |
140 |
valproic acid |
102 |
p-aminosalicylate |
141 |
vancomycin |
103 |
palonosetron |
142 |
vardenafil |
104 |
pantoprazole |
143 |
venlafaxine |
105 |
paroxetine |
144 |
warfarin |
106 |
peginterferon alfa 2a |
145 |
zanamivir |
107 |
peginterferon alfa 2b |
146 |
zolpidem |
147 Specify: |
|||
148 Specify: |
|||
149 Specify: |
|||
150 Specify: |
|||
151 Specify: |
VII. INPATIENT LABORATORY TEST RESULTS |
||||||||||||
Is there documentation of any of the following laboratory test results during this inpatient stay?
|
||||||||||||
Laboratory tests performed closest to admission: (select all that are documented)
|
||||||||||||
|
Result |
|
||||||||||
Undetectable |
Value |
Units (select one, where applicable) |
||||||||||
1 |
|
|
Cells/ mm3 or µL
|
documented |
||||||||
2 |
|
|
% |
|
||||||||
3 |
|
|
Copies/mL
|
documented |
||||||||
|
Lower
Limit of Detection for HIV Viral Load Test Used:
|
|
||||||||||
4 |
|
|
Units /L
|
documented |
||||||||
5 |
|
|
Units/L
|
documented |
||||||||
6 (Creat, Cr) |
|
|
mg/dL
|
documented |
||||||||
Laboratory tests performed closest to discharge: (select all that are documented)
|
||||||||||||
|
Result |
|
||||||||||
Undetectable |
Value |
Units (select one, where applicable) |
||||||||||
1 |
|
|
Cells/ mm3 or µL
|
documented |
||||||||
2 |
|
|
% |
|
||||||||
3 |
|
|
Copies/mL
|
documented |
||||||||
|
Lower
Limit of Detection for HIV Viral Load Test Used:
|
|
||||||||||
4 |
|
|
Units /L
|
documented |
||||||||
5 |
|
|
Units/L
|
documented |
||||||||
6 (Creat, Cr) |
|
|
mg/dL
|
documented |
||||||||
INFECTIOUS DISEASE TESTS: Hepatitis A, B, C |
||||||||||||
|
Pos(+) |
Neg(-) |
Indeterminate |
Undetectable |
Value |
Units (select one, where applicable) |
||||||
22 (HAV Ab IgG) |
|
|
|
|
|
|
|
|
||||
23 (HAV Ab IgM) |
|
|
|
|
|
|
|
|
||||
24 (HAV Ab total) |
|
|
|
|
|
|
|
|
VII. INPATIENT LABORATORY TEST RESULTS cont’d |
|||||||||||
|
Pos(+) |
Neg(-) |
Indeterminate |
Undetectable |
Value |
Units (select one, where applicable) |
|||||
25 (HBc Ab IgG) |
|
|
|
|
|
|
|
|
|||
26 (HBc Ab IgM) |
|
|
|
|
|
|
|
|
|||
27 (HBc Ab total) |
|
|
|
|
|
|
|
|
|||
28
|
|
|
|
|
|
|
|
|
|||
29 (HBs IgG Ab)
|
|
|
|
|
|
|
|
|
|||
30 (HBs Ab) |
|
|
|
|
|
|
|
|
|||
31 (Hepatitis B e-antigen) |
|
|
|
|
|
|
|
|
|||
32 (Hepatitis B surface antigen) |
|
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
IU/mL
|
documented |
||||
|
Lower
Limit of Detection for HBV DNA (PCR) Test Used:
|
|
|||||||||
|
|||||||||||
|
Pos(+) |
Neg(-) |
Indeterminate |
Undetectable |
Value |
Units (select one, where applicable) |
|||||
34 or RIBA |
|
|
|
|
|
|
|
|
|||
35 |
|
|
|
|
|
|
|
|
|||
36 qualitative |
|
|
|
|
|
|
|
|
|||
quantitative (PCR) |
|
|
|
|
|
IU/mL
|
documented |
||||
|
Lower
Limit of Detection for HCV RNA (PCR) Test Used:
|
|
|||||||||
|
MMP SPIF v7.1.0
Abstraction
MMP Participant ID: Facility ID:
(ID of facility where abstraction is being conducted)
Date of Admission:
Mo.
Day
Year
VIII. REMARKS |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Page
File Type | application/msword |
File Title | Medical monitoring project (MMP) |
Author | Rita Morgan |
Last Modified By | Bonds, Constance (CDC/OID/NCHHSTP) |
File Modified | 2012-02-06 |
File Created | 2011-12-16 |